{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:37:36Z","timestamp":1786649856951,"version":"build-2736575974"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.4103\/0973-1482.154928","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T01:07:21Z","timestamp":1455844041000},"page":"1042-1042","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Second primary malignancies in chronic myeloid leukemia patients"],"prefix":"10.4103","volume":"11","author":[{"given":"Tugce","family":"Caliskan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Emre","family":"Eskazan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey"},{"name":"Division of Hematology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1182\/blood-2011-06-362889","article-title":"Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies","volume":"118","author":"Verma","year":"2011","journal-title":"Blood"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4149\/neo_2011_03_256","article-title":"Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia","volume":"58","author":"Voglova","year":"2011","journal-title":"Neoplasma"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1182\/blood.V124.21.154.154","article-title":"Second malignancies following treatment of chronic myeloid leukemia in the tyrosine kinase inhibitor era","volume":"124","author":"Gunnarsson","year":"2014","journal-title":"Blood"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood.V124.21.1801.1801","article-title":"Chronic myeloid leukemia in chronic phase: Survival in the era of tyrosine kinase inhibitors is similar to that of the general population in all age groups","volume":"124","author":"Sasaki","year":"2014","journal-title":"Blood"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.4103\/0973-1482.146095","article-title":"Newly diagnosed breast cancer in a patient receiving imatinib mesylate","volume":"10","author":"Kaygusuz-Atagunduz","year":"2014","journal-title":"J Cancer Res Ther"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:13Z","timestamp":1786647553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.154928","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}